Diego Macias Saint-Gerons

Dr. Diego Macias Saint-Gerons

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FCFerrán Catalá-López
Ferrán Catalá-López
BHBrian Hutton
Brian Hutton
ANAmparo Núñez-Beltrán
Amparo Núñez-Beltrán
MPMatthew J Page
Matthew J Page
MRManuel Ridao
Manuel Ridao
DMDavid Moher
David Moher
Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in childhood. A wide variety of treatments have been used for the management of ADHD. We aimed to compare the efficacy and safety of pharmacological, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. We performed a systematic review with network meta-analyses. Randomised controlled trials (≥ 3 weeks follow-up) were identified from published and unpublished sources through searches in PubMed and the Cochrane Library (up to April 7, 2016). Interventions of interest were pharmacological (stimulants, non-stimulants, antidepressants, antipsychotics, and other unlicensed drugs), psychological (behavioural, cognitive training and neurofeedback) and complementary and alternative medicine (dietary therapy, fatty acids, amino acids, minerals, herbal therapy, homeopathy, and physical activity). The primary outcomes were efficacy (treatment response) and acceptability (all-cause discontinuation). Secondary outcomes included discontinuation due to adverse events (tolerability), as well as serious adverse events and specific adverse events. Random-effects Bayesian network meta-analyses were conducted to obtain estimates as odds ratios (ORs) with 95% credibility intervals. We analysed interventions by class and individually. 190 randomised trials (52 different interventions grouped in 32 therapeutic classes) that enrolled 26114 participants with ADHD were included in complex networks. At the class level, behavioural therapy (alone or in combination with stimulants), stimulants, and non-stimulant seemed significantly more efficacious than placebo. Behavioural therapy in combination with stimulants seemed superior to stimulants or non-stimulants. Stimulants seemed superior to behavioural therapy, cognitive training and non-stimulants. Behavioural therapy, stimulants and their combination showed the best profile of acceptability. Stimulants and non-stimulants seemed well tolerated. Among medications, methylphenidate, amphetamine, atomoxetine, guanfacine and clonidine seemed significantly more efficacious than placebo. Methylphenidate and amphetamine seemed more efficacious than atomoxetine and guanfacine. Methylphenidate and clonidine seemed better accepted than placebo and atomoxetine. Most of the efficacious pharmacological treatments were associated with harms (anorexia, weight loss and insomnia), but an increased risk of serious adverse events was not observed. There is lack of evidence for cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine. Overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence; consequently, results should be interpreted with caution. Clinical differences may exist between the pharmacological and non-pharmacological treatment used for the management of ADHD. Uncertainties about therapies and the balance between benefits, costs and potential harms should be considered before starting treatment. There is an urgent need for high-quality randomised trials of the multiple treatments for ADHD in children and adolescents. PROSPERO, number CRD42014015008.

1 October 2018 in The Lancet Psychiatry
Verified
Journal Article
Closed access
SRSudha R Raman
Sudha R Raman
KMKenneth K C Man
Kenneth K C Man
SBShahram Bahmanyar
Shahram Bahmanyar
ABAnick Berard
Anick Berard
SBScott Bilder
Scott Bilder
IWIan Chi Kei Wong
Ian Chi Kei Wong

8 March 2016 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
FCFerrán Catalá-López
Ferrán Catalá-López
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons
DGDiana González-Bermejo
Diana González-Bermejo
GRGiuseppe M. Rosano
Giuseppe M. Rosano
BDBarry R. Davis
Barry R. Davis
BHBrian Hutton
Brian Hutton
Medications aimed at inhibiting the renin–angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary endpoints were cardiovascular mortality, myocardial infarction, and stroke—singly and as a composite endpoint, major cardiovascular outcome—and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality—singly and as a composite endpoint, progression of renal disease. Secondary endpoints were angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 participants), with a total of 14 different regimens, were pooled using network meta-analyses. When compared with ACE inhibitor, no other RAS blocker used in monotherapy and/or combination was associated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0.90–1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79–1.19), DR inhibitor plus ACE inhibitor (1.32; 95% CrI 0.96–1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73–1.38). For the risk of progression of renal disease, no significant differences were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90–1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72–1.29), DR inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65–1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78–1.84). No significant differences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine. Findings were limited by the clinical and methodological heterogeneity of the included studies. Potential inconsistency was identified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for these single endpoints. In adults with diabetes, comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. Compared with monotherapies, the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outcomes. Clinicians should discuss the balance between benefits, costs, and potential harms with individual diabetes patients before starting treatment. PROSPERO CRD42014014404 Chronic high blood pressure can damage blood vessels, heart, and kidneys, and cause cardiovascular and kidney (or renal) disease. Diabetes increases the risk for high blood pressure. An estimated two-thirds of adults with diabetes have high blood pressure or take blood-pressure-reducing drugs (also called antihypertensives). Because diabetes itself increases the risk for heart and kidney diseases, controlling blood pressure is important. Several of the drugs commonly prescribed to patients with diabetes target the renin–angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance. When renal blood flow is low, kidney cells produce renin and secrete it into the blood stream. Renin in the blood generates a protein called angiotensin I. The angiotensin-converting enzyme (ACE) in the lungs subsequently converts angiotensin I to angiotensin II, and angiotensin II docks with its partner, the angiotensin receptor. This then leads to a signaling cascade that causes blood vessels to constrict and the kidneys to secrete water and salt into the blood, resulting in increased blood pressure. Drugs that interrupt different steps in the cascade can lower blood pressure and thereby prevent cardiovascular and renal disease. In addition to their blood-pressure-lowering effects, some RAS blockers have also been shown to protect heart and kidney function through other mechanisms. RAS blockers fall into three main classes: ACE inhibitors block the conversion of angiotensin I into angiotensin II, angiotensin receptor blockers (ARBs) prevent angiotensin II from activating the angiotensin receptor, and direct renin inhibitors inhibit the production of angiotensin I. As many adults with diabetes are prescribed RAS blockers and likely need to take them or related drugs for the rest of their lives, the question of which drug (or drug combination) has the best results and the least side effects is important. Data from many randomized controlled trials (RCTs, which are the most rigorous clinical tests) have generated results that address this question. Their combined analysis, however, is complicated because the trials often don’t compare all treatments directly, don’t use the exact same treatments in patients with the exact same conditions, or don’t measure the exact same outcomes. Nonetheless, scientists have developed methods to analyze such complex data, including a method called network meta-analysis, which helps to integrate and synthesize diverse results to determine the relative merits of multiple treatments. Here the researchers apply network meta-analysis to all available data from RCTs in which adults with diabetes were given RAS blockers, alone or in combination with other high blood pressure treatments, and that measured cardiovascular or renal outcomes. The researchers started with a systematic search of the medical literature for RCTs that tested RAS blockers alone or in combination in adults with diabetes. They also contacted the sponsors...

1 December 2015 in Medicina Clinica
Verified
Journal Article
Closed access
FCFerrán Catalá-López
Ferrán Catalá-López
ICInmaculada Corrales
Inmaculada Corrales
CFCésar de la Fuente-Honrubia
César de la Fuente-Honrubia
DGDiana González-Bermejo
Diana González-Bermejo
GMGloria Martín-Serrano
Gloria Martín-Serrano
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons

1 June 2013 in Revista Espanola de Salud Publica
Verified
Journal Article
Open access
PDF file
MSMaría Pilar Vicente Sánchez
María Pilar Vicente Sánchez
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons
CHCésar de la Fuente Honrubia
César de la Fuente Honrubia
DBDiana González Bermejo
Diana González Bermejo
DCDolores Montero Corominas
Dolores Montero Corominas
FCFerrán Catalá-López
Ferrán Catalá-López
Fundamentos: Los ansiolíticos y los hipnóticos han sido durante años uno de los grupos farmacológicos más prescritos en la mayoría de países desarrollados. El objetivo principal del presente trabajo fue explorar el patrón de uso de ansiolíticos e hipnóticos en España durante el período 2000-2011 y comparar su incremento con el de cinco países europeos. Método: Estudio ecológico descriptivo del consumo en España a partir de datos de medicamentos dispensados en oficina de farmacia y facturados a través de receta oficial con cargo al Sistema Nacional de Salud. El consumo anual y total se expresó en dosis diarias definidas por 1.000 habitantes y día (DDD/1.000 hab/día) en cada subgrupo terapéutico, principio activo y atendiendo a la semivida plasmática. También se establecieron comparaciones aproximativas con otros países. Resultados: El uso de ansiolíticos e hipnóticos fue de 56,7 DDD/1.000 hab/día en el año 2000 y 82,9 DDD/1.000 hab/día en el año 2011 (incremento del 46,1% en el período). Lorazepam y alprazolam fueron los ansiolíticos más consumidos (20,5 y 15,6 DDD/1.000 hab/día en 2011, respectivamente), mientras que lormetazepam lo fue del grupo de los hipnóticos (18,3 DDD/1.000 hab./día en 2011). En términos relativos, lormetazepam y zolpidem fueron los hipnóticos que más incrementaron su uso (103,3% y 85,1%, respectivamente) mientras que lorazepam e hidroxicina lo fueron entre los ansiolíticos (75,1% y 72,8%, respectivamente). En España (período 2003-2010), el incremento total en el consumo de ansiolíticos e hipnóticos fue de +34,3%, siendo del +24,0% para Portugal, +4,0% para Italia y -6,1% para Francia. Conclusiones: Durante el período estudiado, el consumo de ansiolíticos e hipnóticos se incrementó en España, siendo el incremento superior incluso al reportado en otros países europeos.

16 January 2014 in European Addiction Research
Verified
Journal Article
Closed access
PDF file
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
MGMireille Gony
Mireille Gony
ACAlfonso Carvajal
Alfonso Carvajal
DSDiego Macias Saint-Gerons
Diego Macias Saint-Gerons
ACAnita Conforti
Anita Conforti
TGThe OSIAP Europe Study Group
The OSIAP Europe Study Group
Aim: To identify prescription drugs involved in falsified prescriptions in community pharmacies in 6 European countries. Methods: A cross-sectional survey among 2,105 community pharmacies in Belgium, France, Italy, the Netherlands, Spain and Sweden was carried out to collect all suspect prescription forms. For each reported drug, the number of reported falsified prescriptions per thousand inhabitants was estimated. A falsification ratio was calculated by dividing the number of reports by the number of defined daily doses per 1,000 inhabitants per day for this drug, computed from national sale or reimbursement data. Results: On 862 prescription forms, benzodiazepines (zolpidem, bromazepam, alprazolam), buprenorphine (as an opioid maintenance drug) and tramadol were the most frequently reported. Depending on their level of use in each country, methylphenidate, morphine and flunitrazepam presented the highest falsification ratios, particularly in Spain, Belgium and France. Conclusions: Stimulants, opioids and some benzodiazepines were the most frequently reported drugs in this survey on falsified prescriptions, but differences between countries were observed.